Loading cancer entity…
Loading cancer entity…
Clinical trials
4,033 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (699)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01015196 | Prospective Randomized Study Comparing One or Two High Dose Chemotherapy Regimen Followed by Autologous Stem Cell Transplantation(AML2001) | completed | Phase 2 / Phase 3 | 832 | Nantes University HospitalOTHER | 1 | Nov 18, 2009 | clinicaltrials |
| NCT00042016 | Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec) | completed | Phase 2 | 40 | Astex Pharmaceuticals, Inc.INDUSTRY | 2 | Oct 14, 2009 |
| clinicaltrials |
| NCT00512083 | Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia | completed | Phase 2 | 70 | Antisoma ResearchINDUSTRY | 2 | Sep 25, 2009 | clinicaltrials |
| NCT00401739 | Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia | completed | Phase 1 | 40 | CSL LimitedINDUSTRY | 1 | Sep 16, 2009 | clinicaltrials |
| NCT00276926 | Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias | unknown | Phase 2 | — | University of BolognaOTHER | 1 | Sep 15, 2009 | clinicaltrials |
| NCT00530699 | Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML) | completed | Phase 1 | 30 | AstraZenecaINDUSTRY | 1 | Sep 11, 2009 | clinicaltrials |
| NCT00966810 | Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion | unknown | Phase 2 / Phase 3 | 40 | Rambam Health Care CampusOTHER | 1 | Aug 27, 2009 | clinicaltrials |
| NCT00037583 | Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia | completed | Phase 2 | 69 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 0 | Aug 21, 2009 | clinicaltrials |
| NCT00373373 | Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML | completed | Phase 2 | 200 | University Hospital MuensterOTHER | 1 | Aug 19, 2009 | clinicaltrials |
| NCT00306332 | T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation | terminated | Phase 3 | 250 | Radboud University Medical CenterOTHER | 1 | Aug 18, 2009 | clinicaltrials |
| NCT00510939 | Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia(HEMOS AML 0106) | unknown | Phase 2 | 72 | University of BolognaOTHER | 1 | Aug 14, 2009 | clinicaltrials |
| NCT00598624 | Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)(AlloTreo) | unknown | Phase 2 | 175 | IRCCS San RaffaeleOTHER | 1 | Aug 11, 2009 | clinicaltrials |
| NCT00931138 | Treatment of Acute Myeloid Leukemia (AML) in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 2(ALFA 9801) | completed | Phase 3 | 420 | Acute Leukemia French AssociationOTHER | 1 | Jul 2, 2009 | clinicaltrials |
| NCT00925873 | GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the Elderly | completed | Phase 3 | 303 | French Innovative Leukemia OrganisationOTHER | 1 | Jun 22, 2009 | clinicaltrials |
| NCT00352677 | Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia | completed | Phase 1 | 100 | CytRxINDUSTRY | 3 | Jun 1, 2009 | clinicaltrials |
| NCT00543972 | Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia | terminated | Phase 1 | 12 | SanofiINDUSTRY | 3 | May 14, 2009 | clinicaltrials |
| NCT00391014 | Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis(AMBINEB) | completed | Phase 2 | 150 | PETHEMA FoundationOTHER | 1 | May 12, 2009 | clinicaltrials |
| NCT00506402 | A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies | completed | Phase 1 | 30 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | May 5, 2009 | clinicaltrials |
| NCT00880243 | Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML) | completed | Phase 3 | 473 | Acute Leukemia French AssociationOTHER | 0 | Apr 13, 2009 | clinicaltrials |
| NCT00064584 | Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML) | completed | Phase 1 | 60 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 24, 2009 | clinicaltrials |
| NCT00866073 | Study of Low-Dose Intravenous Decitabine in Patients Aged > 60 Years With Acute Myeloid Leukemia | completed | Phase 2 | 238 | University Hospital FreiburgOTHER | 2 | Mar 20, 2009 | clinicaltrials |
| NCT00854841 | The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder | available | — | — | Pusan National University HospitalOTHER | 0 | Mar 3, 2009 | clinicaltrials |
| NCT00257647 | Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML) | completed | — | 25 | Hadassah Medical OrganizationOTHER | 1 | Feb 18, 2009 | clinicaltrials |
| NCT00145613 | Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies | completed | Phase 2 | 25 | St. Jude Children's Research HospitalOTHER | 1 | Feb 13, 2009 | clinicaltrials |
| NCT00461929 | Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib(GIST) | terminated | Phase 4 | 68 | University Health Network, TorontoOTHER | 1 | Feb 13, 2009 | clinicaltrials |
| NCT00146120 | Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result | completed | Phase 3 | 400 | University of UlmOTHER | 2 | Feb 9, 2009 | clinicaltrials |
| NCT00707408 | High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 15 | Nantes University HospitalOTHER | 1 | Feb 2, 2009 | clinicaltrials |
| NCT00086099 | Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 54 | MedImmune LLCINDUSTRY | 2 | Jan 29, 2009 | clinicaltrials |
| NCT00143559 | Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies | completed | Phase 2 | 17 | St. Jude Children's Research HospitalOTHER | 1 | Jan 29, 2009 | clinicaltrials |
| NCT00152139 | Stem Cell Transplantation for Patients With Hematologic Malignancies | completed | Phase 3 | 33 | St. Jude Children's Research HospitalOTHER | 1 | Jan 29, 2009 | clinicaltrials |
| NCT00516152 | Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT | completed | Phase 2 | 36 | University of California, San FranciscoOTHER | 1 | Jan 26, 2009 | clinicaltrials |
| NCT00815568 | Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI) | unknown | Phase 2 | 114 | Samsung Medical CenterOTHER | 1 | Dec 30, 2008 | clinicaltrials |
| NCT00390897 | Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia | completed | Phase 4 | 360 | PETHEMA FoundationOTHER | 1 | Nov 27, 2008 | clinicaltrials |
| NCT00487448 | SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia(FLAG-IDA) | completed | Phase 4 | 200 | PETHEMA FoundationOTHER | 1 | Nov 19, 2008 | clinicaltrials |
| NCT00488709 | Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia(FLAT) | completed | Phase 4 | 47 | PETHEMA FoundationOTHER | 1 | Nov 18, 2008 | clinicaltrials |
| NCT00114764 | Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML) | completed | Phase 2 | 84 | AmgenINDUSTRY | 0 | Oct 31, 2008 | clinicaltrials |
| NCT00594555 | A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia | withdrawn | Phase 2 | 20 | University of CincinnatiOTHER | 1 | Oct 31, 2008 | clinicaltrials |
| NCT00559221 | FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML | unknown | Phase 2 | 37 | Cooperative Study Group A for HematologyNETWORK | 1 | Oct 15, 2008 | clinicaltrials |
| NCT00001144 | Modified Bone Marrow Stem Cell Transplantation for Chronic Myelogenous Leukemia | completed | Phase 2 | 50 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Oct 7, 2008 | clinicaltrials |
| NCT00728520 | Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction Therapy | unknown | Phase 2 | 40 | Kansas City Veteran Affairs Medical CenterFED | 1 | Aug 6, 2008 | clinicaltrials |
| NCT00700544 | Treatment Outcome in Elderly Patients | completed | Phase 3 | 330 | University Hospital, GrenobleOTHER | 1 | Jun 18, 2008 | clinicaltrials |
| NCT00675870 | Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia | unknown | Phase 2 | 65 | NuRx Pharmaceuticals, Inc.INDUSTRY | 1 | May 12, 2008 | clinicaltrials |
| NCT00667927 | Autologous Bone Marrow Transplant for Children With Acute Myelogenous Leukemia (AML) in First Complete Remission | completed | Phase 1 | 17 | St. Jude Children's Research HospitalOTHER | 1 | Apr 28, 2008 | clinicaltrials |
| NCT00129168 | Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 100 | Kanisa PharmaceuticalsINDUSTRY | 0 | Apr 1, 2008 | clinicaltrials |
| NCT00233909 | A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 55 | Kanisa PharmaceuticalsINDUSTRY | 0 | Apr 1, 2008 | clinicaltrials |
| NCT00465933 | Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) | completed | Phase 4 | — | PETHEMA FoundationOTHER | 1 | Mar 31, 2008 | clinicaltrials |
| NCT00001432 | The Collection of Peripheral Blood Lymphocytes and Marrow Progenitor Cells From Normal Volunteers and Volunteers With Lymphoid or Hematologic Malignancies | completed | — | 75 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001748 | HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies | completed | Phase 1 | 35 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00363025 | A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia. | terminated | Phase 3 | 465 | Acute Leukemia French AssociationOTHER | 1 | Feb 21, 2008 | clinicaltrials |
| NCT00274248 | MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia | completed | Phase 1 | — | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 11, 2008 | clinicaltrials |
Data updated 23 days agoSource updated Nov 18, 2009source: clinicaltrials